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Abstract: Virtual reality (VR) was introduced to maximize the effect of cognitive behavioral therapy
(CBT) by efficiently performing exposure therapy. The purpose of this study was to find out whether
VR-based individual CBT with relatively few treatment sessions is effective in improving social
anxiety disorder (SAD). This therapy was applied to 115 patients with SAD who were retrospectively
classified into 43 patients who completed the nine or 10 sessions normally (normal termination
group), 52 patients who finished the sessions early (early termination group), and 20 patients who
had extended the sessions (session extension group). The Brief Fear of Negative Evaluation Scale
(BFNE) scores tended to decrease in all groups as the session progressed, and the slope of decrease
was the steepest in the early termination group and the least steep in the session extension group.
Severity of social anxiety in the last session and symptom reduction rate showed no significant group
difference. Our findings suggest that short-term VR-based individual CBT of nine to 10 sessions
may be effective. When the therapeutic effect is insufficient during this period, the additional benefit
may be minimal if the session is simply extended. The improvement in the early termination group
suggests that even shorter sessions of five or six can also be effective.
Keywords: social anxiety disorder; virtual reality; individual cognitive behavioral therapy; exposure
therapy; number of sessions
1. Introduction
Social anxiety disorder (SAD) characterized by a marked fear about social situations,
and avoidance of social stimuli [1] is a common psychiatric disorder with lifetime preva-
lence between 7% and 13% [2,3]. Cognitive behavioral therapy (CBT) has been used as
a major tool for the treatment of SAD [4,5]. Among the techniques of CBT, exposure
therapy is often used to treat a variety of anxiety disorders [6,7]. In particular, in vivo
exposure to social situations has been reported to be an effective way to alleviate social
anxiety and overcome social avoidance [8,9]. For example, Haug et al. [8] reported that
between 24 weeks of treatment and 52 weeks of follow-up evaluation, the Clinical Global
Impression—Social Phobia overall severity score decreased by 0.45 in the in vivo exposure
group, compared to 0.25 in the placebo group.
However, in vivo exposure can be impractical to use in clinical practice due to several
issues, such as cost, time consumption, audience recruitment, and control management.
Patients with SAD can avoid experiencing such real-world situations because of their
symptoms. Virtual reality (VR) exposure can be an alternative to in vivo exposure in that
VR can induce emotional responses similar to reality and its application is acceptable to
patients and produces a good therapeutic effect [10]. As a result of these advantages, VR
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exposure therapy (VRET) is being used more and more often in the clinical field to treat
various mental disorders [11,12]. In particular, VRET has been reported to be as effective as
traditional CBT in treating public speaking anxiety [13,14] and even generalized SAD [15].
A recent controlled trial for patients with SAD showed that VRET was more effective at
post-treatment and more practical for therapists than in vivo exposure therapy [16]. A
recent meta-analysis study suggested that the efficacy of VRET for SAD continued over the
long-term follow-up period with an effect size (Hedges′ g) of −0.86 at post-intervention,
–1.03 at three months, −1.14 at six months, and −0.74 at 12 months [17]. Our research
team also reported that the use of VR exposure technology was effective in reducing social
anxiety even in a self-training environment; the Liebowitz Social Anxiety Scale (LSAS)
score decreased 19.8% in patients with social anxiety disorder [18].
In addition to exposure therapy, other forms of CBT have also been reported to
be effective in treating SAD, examples of which include group therapy [19], individual
cognitive therapy [20], intensive group cognitive therapy [21], social skills training [22],
relaxation training [23], and mindfulness-based stress reduction [24]. Meta-analytic reviews
have reported that combining two or more of these types of CBT is also useful for treating
SAD, and both individual and group formats are effective [25,26]. In addition, in order
to maintain the therapeutic effect for a sufficiently long period after CBT, it is necessary
to weaken the negative beliefs of patients with SAD, and for this, cognitive restructuring
through intensive cognitive therapy may be essential [27]. Taken together, it may be
possible to treat patients with SAD only with VRET, but combining this with other forms
of CBT is likely to improve treatment effectiveness. For example, VR-based individual CBT
may include cognitive restructuring and relaxation training as well as VRET.
There is no doubt about the usefulness of CBT as such, but there are still no definitive
guidelines on how many treatment sessions should be conducted to effectively treat SAD.
Previous studies have reported that long-term treatment of 14 or 16 sessions, once a week,
was effective [16,28], while short-term treatment of eight sessions was also effective [13].
Our research team reported that eight intensive exposure sessions for 2 weeks were effec-
tive enough to reduce social anxiety [18]. Due to the diversity of the treatment session
composition of previous studies, it has not been established how many treatment sessions
are appropriate even for VR-based individual CBT that maximizes the effect of CBT by
efficiently performing exposure therapy.
The purpose of this study was to find out whether VR-based individual CBT with
relatively few treatment sessions of nine or 10 times is effective in improving SAD. For this
purpose, we performed a retrospective analysis of the data from patients who received
VR-based individual CBT for the treatment of SAD, the core of which was to compare
psychological measures among the group who ended earlier than eight sessions, the
group who normally ended nine or 10 sessions, and the group who conducted longer
than 11 sessions. We hypothesized that nine or 10 sessions of therapy would be sufficient
to alleviate social anxiety, and in some cases, even short-term therapy of eight or fewer
sessions could achieve the desired outcome, whereas there would be little additional benefit
that could be gained from long-term therapy of longer than 11 sessions.
2. Methods
2.1. Participants
Among patients with SAD who visited the department of psychiatry in Gangnam
Severance Hospital, 115 patients who participated in VR-based CBT were the targets of
the retrospective analysis. Psychiatric diagnosis was based on the Mini-International
Neuropsychiatric Interview (MINI) [29], and exclusion criteria included other significant
psychiatric illnesses except SAD, substance abuse, any neurological or serious physical
disorders, and a pregnancy. This study was approved by the institutional review board of
Gangnam Severance Hospital (3-2020-0431).
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2.2. Procedure
All patients participated in VR-based CBT for nine or 10 weeks in one session per week.
These sessions were conducted one-to-one between a therapist skilled in CBT (J.H.L.) and a
patient in the VR clinic of Gangnam Severance Hospital. VR-based CBT included cognitive
restructuring training, relaxation training, and VRET. Cognitive restructuring training was
to address the frequency and strength of beliefs to reduce negative self-defeating thoughts
and increase positive well-being-enhancing thoughts [30]. Relaxation training consisted
of diaphragmatic breathing and progressive muscle relaxation [31]. VRET was conducted
using the desktop-based program or the mobile version consisting of three environments,
in which 12 situations and 36 topics were provided with four different levels of difficulty
in a way that the number of virtual audience appearing increased (see the sample videos:
https://youtu.be/LxfSPaSJSTE accessed on 1 December 2020). The program featured
an automatic monitoring system of the participants′ eye movement, speaking time, and
heart rate for immediate feedback. A further description of VRET is detailed in a previous
paper [18].
During the VR-based CBT period, the progression of sessions was in the following
sequence and contents: Session 1, orientation and psychoeducation for SAD; Session 2,
cognitive restructuring training (recognizing automatic thinking and cognitive errors);
Session 3, cognitive restructuring training (attacking cognitive errors and deriving ratio-
nal responses) and VRET (level 1, conversation with some people); Session 4, cognitive
restructuring training (correcting irrational beliefs and becoming a self-therapist) and
VRET (level 2, presentation in front of a small audience size); Session 5, relaxation training
(diaphragmatic breathing) and VRET (level 3, presentation in front of a moderate audience
size); Session 6, relaxation training (progressive muscle relaxation) and VRET (level 3,
presentation in front of a moderate audience size); Session 7, VRET (level 4, presentation
in front of a large audience size); Session 8, VRET (level 4, presentation in front of a large
audience size); Session 9, VRET (special level, presentation in front of evaluators); and
Session 10, VRET (special level, presentation in front of evaluators).
In principle, this training schedule was applied to all participants, but it was flexibly
applied depending on the participants′ symptoms and learning level. Ten sessions were
the default, but when nine sessions yielded sufficient treatment effects, the VR-based CBT
was terminated normally under the agreement of the therapist and participant. If it was
judged that sufficient therapeutic effect was not obtained by the 9th session, the VR-based
CBT could be extended to more than 11 sessions with the agreement of the two. In these
extended sessions, the contents of training were basically re-learning over and over again
what was included up to the 10th session, and the termination was made between the 11th
and 20th sessions by the agreement between the two.
2.3. Measurements
Prior to the beginning of the first session, participants completed a set of question-
naires. The first one was the Brief Fear of Negative Evaluation Scale (BFNE), which is a
12-item 5-point Likert scale (1–5) to assess anxiety with perceived negative evaluation [32].
The second one was the LSAS, which is a 24-item 4-point Likert scale (0–3), assessing the
level of social anxiety and the avoidance of different social situations [33]. The third one
was the Social Phobia Scale (SPS), which is a 20-item 5-point Likert scale (0–4), assessing
fears of being scrutinized during routine activities [34]. The fourth one was the Social
Interaction Anxiety Scale (SIAS), which is a 20-item 5-point Likert scale (0–4), measuring
complementary aspects of social phobia [34]. These measures were reevaluated after the
last session. Given that the BFNE was sensitive to treatment-related change and thus useful
as an outcome measure in SAD [35], the BFNE was repeatedly evaluated in each session.
2.4. Statistical Analysis
The participants were classified into the following three groups according to the num-
ber of sessions completed. The participants who did not reach the 9th session, the criterion
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for normal termination, were referred to as the early termination group. The participants
who completed the 9th or 10th session were referred to as the normal termination group.
The participants who extended the session more than 11 times by agreement with the
therapist were referred to as the session extension group.
Demographic variables and psychological measures at baseline were compared among
the three groups using analysis of variance (ANOVA) or chi-squared test. The significance
of changes in the BFNE score according to the progress of treatment sessions and their
difference among the three groups were analyzed using the linear mixed model (specifi-
cally, random intercept model) analysis. For this analysis, after missing data were inputted
using the last observation carried forward (LOCF) method, the estimated BFNE scores
were counted in all groups and compared using ANOVA. Independent variables as pos-
sible predictors for the linear mixed models included gender, age, education years, job
status, marital status, medication status, group, number of sessions, and group-by-session
interaction. In the normal termination and session extension groups, the changes before
and after the therapy of the scale scores other than the BFNE score were analyzed using
ANOVA. For all scale scores, the symptom reduction rate was calculated by the formula of
[(pretreatment score − posttreatment score) ÷ pretreatment score] × 100%, and the group
difference in this reduction rate was assessed using ANOVA or Student t-tests. For all
the ANOVAs described above, post-hoc tests for significant results were performed using
independent or paired t-tests. The significance level in all analyses was set at p < 0.05, and
Bonferroni correction was additionally applied to post-hoc tests. All statistical analyses
were conducted using SPSS statistics, v. 25.0 (IBM, Armonk, NY, USA), SAS version 9.4
(SAS Institute Inc., Cary, NC, USA), or R package version 4.0.3 (http://www.R-project.org
accessed on 15 December 2020).
3. Results
3.1. Participant Characteristics
Among 115 participants, 52 were in the early termination group, 43 were in the normal
termination group, and 20 were in the session extension group. The total number of
sessions was 5.2 ± 1.9 in the early termination group, 9.4 ± 0.9 in the normal termination
group, and 13.5 ± 2.7 in the session extension group. Demographic variables and measures
of social anxiety in these three groups before VR-based CBT are given in Table 1. There
were no significant group differences in demographic information. There were also no
significant differences in the BFNE, LSAS-avoidance, and SIAS scores among the three
groups, whereas the LSAS-anxiety and SPS scores showed a significant group difference
(F2112 = 6.19, p = 0.003; F281 = 5.35, p = 0.007, respectively). Post-hoc tests showed that
both the LSAS-anxiety and SPS scores were significantly higher in the session extension
group than in the early and normal termination groups (t112 = 3.44, p = 0.003 and t112 = 2.95,
p = 0.012; t81 = 3.05, p = 0.009 and t81 = 2.98, p = 0.012; respectively), whereas those scores
did not significantly differ between the early and normal termination groups.
3.2. Changes in the BFNE Scores According to Session Progress
Figure 1 shows plots of the mean BFNE scores and the number of participants in
each session and each group. Considering that the number of sessions completed in each
group varied depending on the participants, Figure 2 presents changes in the mean BFNE
scores from baseline to the last session. The scores in the last session did not significantly
differ among the early termination, normal termination group, and session extension
groups (38.5 ± 10.2, 35.0 ± 9.5, and 40.0 ± 8.1, respectively; F2112 = 2.18, p = 0.097). The
reduction rate of the BFNE score also showed no significant group difference (14.5 ± 15.2%,
18.7 ± 18.2%, and 15.2 ± 21.0%, respectively; F2,112 = 1.76, p = 0.477).
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Table 1. Demographic variables and psychological measures of the early termination, normal termination, and session











Gender, male/female 28/24 32/11 15/5 5.41 0.067
Age, years 34.3 ± 13.3 31.2 ± 15.5 27.6 ± 10.7 1.81 0.169
Education level, years * 14.2 ± 3.2 13.0 ± 3.4 13.5 ± 3.1 1.60 0.207
Job status,
employed/unemployed 22/30 13/30 7/13 1.51 0.471
Marital status,
single/married/divorced 29/20/3 29/12/2 15/5/0 3.33 0.504
Medication,
medicated/unmedicated 28/24 23/20 15/5 3.07 0.215
BFNE 45.2 ± 9.7 43.8 ± 10.4 48.0 ± 6.4 2.07 0.264
LSAS, anxiety 34.1 ± 14.6 35.5 ± 13.9 46.6 ± 11.4 6.19 0.003
LSAS, avoidance 27.7 ± 15.7 31.0 ± 14.8 34.6 ± 10.8 1.70 0.187
SPS 32.2 ± 18.5 32.4 ± 18.0 49.2 ± 17.6 5.35 0.007
SIAS 43.9 ± 21.7 46.6 ± 15.9 56.1 ± 12.7 3.62 0.101
Values are the number of participants for Chi-squared test or mean ± standard deviation for ANOVA. * Education level refers to the
number of years actually attended school. Abbreviation: BFNE, Brief Fear of Negative Evaluation Scale; LSAS, Liebowitz Social Anxiety
Scale; SPS, Social Phobia Scale; SIAS, Social Interaction Anxiety Scale.
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Figure 2. Group-specific changes in the Brief Fear of Negative Evaluation Scale scores for each participant from baseline to
the last session. The number of sessions (NS) varied depending on the participants from one to eight in the early termination
group (ET), nine to ten in the normal termination group (NT), and 11 to 20 in the session extension group (SE). Reduction
rate (RR) = [(score at baseline − score in the last session)/score at baseline] × 100%.
Table 2 presents the estimated mean BFNE scores at baseline and in each session,
which were obtained using the LOCF method, and it shows results from the comparison
among the three groups using ANOVA. From baseline to the second session, the estimated
scores showed no group difference. By the third session, the scores were significantly
higher in the session extension group than in the normal termination group. From the 4th
se sion to the 10th session, they were sig ificantly high r in the ssion extension group
than in the early and normal termination groups. The scores did not differ between the
early and normal termination groups in all sessions. Based on these estimated mean BFNE
scores, the expected reduction rate when the 10th session was completed was 21.9% in the
normal termina ion group, rather high at 28% in t e early interv ntion group, and only
13.9% in the session extension group.
In the linear mixed models exploring associations of possible predictors with fear
of negative evaluation, none of the demographic variables turned out to be significant
pre ictors. Group was also revealed non-significant (F2862 = 2.41, p = 0.091), but the
number of sessions and group-by-session interaction effect were significant (F1862 = 301.77,
p < 0.0001; F2862 = 8.84, p = 0.0002, respectively). Post-hoc tests showed that all of the
early termination, normal termination, and session extension groups showed significant
decreases in the BFNE scores according to session progress (slope [standard error]: −1.31
[0.12], p < 0.0001; −0.95 [0.07], p < 0.0001; and −0.67 [0.09], p < 0.0001, respectively). The
decrease in the scores was significantly steeper with a difference in slope of 0.36 [0.14] in the
early termination group than in the normal termination group (p = 0.011), with a difference
in slope of 0.29 [0.12] in the normal termination group than in the session extension group
(p = 0.015), and with a difference in slope of 0.64 [0.15] in the early termination group than
in the session extension group (p < 0.0001).
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Table 2. Changes in the estimated mean of the Brief Fear of Negative Evaluation Scale scores according to session progress












Baseline 46.0 (1.2) 43.3 (1.3) 48.2 (1.9) 0.089
1 44.7 (1.2) 42.4 (1.3) 47.5 (1.9) 0.074
2 43.4 (1.1) 41.4 (1.3) 46.8 (1.8) 0.057
3 42.1 (1.1) 40.5 (1.2) 46.2 (1.8) 0.041 ET = NT, ET = SE, NT < SE
4 40.8 (1.2) 39.5 (1.2) 45.5 (1.8) 0.028 ET = NT, ET = SE, NT < SE
5 39.4 (1.2) 38.6 (1.2) 44.8 (1.8) 0.019 ET = NT, ET < SE, NT < SE
6 38.1 (1.2) 37.6 (1.2) 44.2 (1.8) 0.012 ET = NT, ET < SE, NT < SE
7 36.8 (1.3) 36.7 (1.3) 43.5 (1.8) 0.008 ET = NT, ET < SE, NT < SE
8 35.5 (1.3) 35.7 (1.3) 42.8 (1.8) 0.005 ET = NT, ET < SE, NT < SE
9 34.2 (1.4) 34.8 (1.3) 42.2 (1.9) 0.004 ET = NT, ET < SE, NT < SE
10 32.9 (1.5) 33.8 (1.3) 41.5 (1.9) 0.003 ET = NT, ET < SE, NT < SE
Values are mean (standard error). Abbreviation: ET, early termination group; NT, normal termination group; SE, session extension group.
3.3. Changes in Other Psychological Measures before and after VR-Based CBT
Table 3 shows the psychological scale scores at baseline and in the last session in
the normal termination and session extension groups. Since participants in the early
termination group did not terminate VR-based CBT in agreement with the therapist, these
scales, evaluated at termination, were not obtained, and thus, they were excluded in this
table. The main effect of group was shown in the LSAS-anxiety, SPS, and SIAS scores (F1107
= 11.27, p = 0.001; F192 = 7.43, p = 0.008; F191 = 5.67, p = 0.019) but not in the LSAS-avoidance
score. Post-hoc t-tests revealed that all of these three scale scores showing the group effect
were significantly higher in the session extension group than in the normal termination
group (all: p < 0.05). The main effect of time was shown in all scale scores (LSAS-anxiety:
F1107 = 16.3, p < 0.001, LSAS-avoidance: F1107 = 8.86, p = 0.004, SPS: F192 = 20.48, p < 0.001,
and SIAS: F191 = 19.86, p < 0.001, respectively). Post-hoc t-tests revealed that the scores in
the last session were significantly lower than those at baseline in all of the four scales (all:
p < 0.01). The group × time interaction effect was not found in all scale scores, and the
reduction rates of all scale scores did not significantly differ between the two groups.
Table 3. Changes in the psychological scale scores in the last session compared with the baseline scores in the normal
termination and session extension groups.
Scale
Normal Termination Group Session Extension Group ReductionRate
Group × Time
Interaction
Baseline Last pa ReductionRate, % Baseline Last p
a Reduction
Rate, % t





















7.7 0.009 20.7 ± 31.7 −0.67 0.507 0.04 0.848
SPS 32.4 ±18.0
22.8 ±




13.9 0.000 43.4 ± 23.4 −1.59 0.121 3.58 0.062
SIAS 46.6 ±15.9
32.9 ±




14.5 0.006 25.8 ± 28.4 −0.26 0.796 0.17 0.680
Values are mean ± standard deviation. Abbreviation: LSAS, Liebowitz Social Anxiety Scale; SPS, Social Phobia Scale; SIAS, Social
Interaction Anxiety Scale. a Paired t-test, b Student t-test, c ANOVA.
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4. Discussion
The core issue of this study was the appropriate number of sessions when performing
VR-based CBT in patients with SAD. Although it has been repeatedly reported that the
treatment effect of VR-based CBT is excellent in SAD, the number of treatment sessions
applied for each report varies considerably from four to 16 [36]. VR-based CBT is superior
to conventional CBT in terms of cost and effort of delivering the treatment [37], yet there is
no controlled study on whether the application of VR to patients with SAD contributes to
the reduction of the number of treatment sessions.
Since our VR-based CBT was based on nine to 10 sessions, the patients who completed
these sessions were defined as the normal termination group. Given that different cut-offs,
from 20 to 50%, have been used in the literature for the definition of response [38], when
20% is considered the minimal response, most of our study′s scale scores appear to have
reached the minimal level of improvement through these numbers of sessions. These
numbers correspond to a study by Kampmann et al. (2016) [15], reporting the results after
performing 10 sessions of VR-based CBT, in which the symptom reduction rate was about
12.2% on the BFNE and 23.6% on the LSAS. Our results showed that this reduction rate
was relatively high on the BFNE (21.9%) and slightly low on the LSAS (19.5%). This is
believed to be because our therapy was not only focused on exposure therapy using VR
but also included cognitive restructuring and relaxation training that did not use VR.
In our VR-based CBT, there were patients who participated in sessions of 11 or
more (average 13.5) without terminating normally in the 9th or 10th session, which was
designated as the session extension group. These patients showed that all scale scores in
the last session decreased to the extent that there was no statistical difference from those
of the normal termination group. However, the slopes representing the rate of decline
in the BFNE score indicated that this group was the least steep among the three groups,
suggesting that they required more sessions to achieve a similar degree of therapeutic
effect as other groups of patients. This inefficiency is likely to be related to their severe
symptoms before the start of treatment, especially with the LSAS-anxiety and SPS scores
significantly being higher than those of the other groups. In general, when predicting the
therapeutic effect of psychotherapy, the baseline symptom severity has been regarded as a
reliable predictor [39]. Even in SAD, the severity of baseline social anxiety was found to be
one of the significant predictors of poor outcome [40].
At the current research level, it is difficult to determine whether long-term treatment
of 11 or more sessions is necessary. The answer to this question cannot be found in
the previous studies that analyzed the effects of VR-based CBT consisting of 12 or more
sessions [14,16,41]. This is because all of them did not report any detailed changes in the
scale scores after session 11, only the pre- and post-treatment scale scores. In fact, patients
in our session extension group originally started with the goal of normal termination but
felt that the treatment effect was insufficient and agreed with the therapist to extend the
sessions. This feeling is reflected in the result that the symptom reduction rate calculated
based on the estimated BFNE score at the 10th session was only 13.9% in this group.
However, even though the therapy was extended, the reduction rate calculated based on
the actual BFNE score at the last session was 15.2%, indicating that, as our hypothesis,
there was little benefit obtained by adding the sessions. In light of these findings, it may
not be recommended to simply extend the treatment sessions based on a patient′s request
to obtain more therapeutic effects rather than the scheduled sessions from the initial plan.
Instead, it may be desirable to add other treatment modalities for this class of patients.
Meanwhile, patients in the early termination group participated only in eight sessions
or less in our VR-based CBT and did not go through a normal termination process. Thus,
it was not possible to determine why they gave up treatment early. However, while their
personal circumstances or disappointment with the degree of improvement may be the
reason, they may have made such a decision because they thought that the treatment was
remarkably effective and they did not need further treatment. The possibility for the latter
seems to be well reflected by the changes in the BFNE scores of this group. They completed
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an average of 5.2 sessions, showing an average reduction rate of 14.5% in their last session,
which was the lowest among the three groups but not statistically different. Therefore,
short-term treatments of five to six sessions may be suitable for rapid responders. This
is supported by a previous report that only four sessions of treatment were effective in
reducing public speaking anxiety [42]. There is a report that VRET consisting of eight
sessions was effective for treating social anxiety, and the therapeutic effect continued
even after one year [11]. However, in our analysis, as it was calculated that their expected
reduction rate based on the estimated BFNE score could have risen to 28.4% if it had reached
normal termination, it seems that the treatment schedule of nine to 10 sessions rather than
early termination may help maximize the treatment effect. Meanwhile, the findings in
this early termination group can have an important economic implication. If a satisfactory
therapeutic effect can be achieved with a small number of VRET sessions, patients will be
able to receive treatment at a lower cost. Accordingly, the number of patients participating
in the treatment may increase, and hospitals may increase the related investment.
Our results should be interpreted within the context of the study′s limitations. In
this study, based on the data of patients with SAD who had already received VR-based
CBT, the analysis was conducted in groups that were retrospectively classified according to
specific criteria, and thus the number of sessions was too diverse and the same evaluation
was not made between groups. For the same reason, demographic variables such as
duration of illness or economic status that could affect outcomes were not included in
the analysis. Therefore, a prospective randomized controlled study is needed to more
accurately evaluate the effect of the number of sessions and the various demographic
variables. In addition, the most important scale analyzed in this study was the BFNE
measured in each session. This scale focuses on the cognitive aspects of patients with SAD
and thus may not reflect patients′ social anxiety and avoidance linearly.
5. Conclusions
VR technology benefits treatment outcomes not only for the cost and effort of de-
livering treatment but also for the effectiveness of treatment. In this retrospective study
for an issue of how many sessions are appropriate when performing VR-based CBT, data
related to the severity of social anxiety obtained from patients with SAD, who received
the therapy, were analyzed focusing on the differences among the three groups, such as
the normal termination, early termination, and session extension groups. In the results,
fear of negative evaluation tended to decrease in all groups as the session progressed, and
the slope of decrease was the steepest in the early termination group and the least steep in
the session extension group. The BFNE scores in the last session and the reduction rates
of the scores showed no significant group difference. Our results suggest that short-term
VR-based individual CBT of nine to 10 sessions may be effective in the treatment of SAD,
and that patients with insufficient therapeutic effect during this period are difficult to
obtain additional benefits even if the treatment is continued for an extended period. In
view of the improvement in patients who finished earlier than normal termination, even
shorter sessions of five or six could be effective in treating SAD. A further randomized
controlled study is needed to assess a difference in effectiveness depending on the number
of sessions more accurately.
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